158 related articles for article (PubMed ID: 21521775)
21. MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.
Fulciniti M; Amodio N; Bandi RL; Munshi M; Yang G; Xu L; Hunter Z; Tassone P; Anderson KC; Treon SP; Munshi NC
Blood; 2014 Apr; 123(17):2673-81. PubMed ID: 24622324
[TBL] [Abstract][Full Text] [Related]
22. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
[TBL] [Abstract][Full Text] [Related]
23. MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer.
Du X; Lin BC; Wang QR; Li H; Ingalla E; Tien J; Rooney I; Ashkenazi A; Penuel E; Qing J
Clin Cancer Res; 2014 Dec; 20(24):6324-35. PubMed ID: 25326231
[TBL] [Abstract][Full Text] [Related]
24. IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia.
Hodge LS; Ziesmer SC; Yang ZZ; Secreto FJ; Gertz MA; Novak AJ; Ansell SM
Blood; 2012 Nov; 120(18):3774-82. PubMed ID: 22976953
[TBL] [Abstract][Full Text] [Related]
25. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
Milowsky MI; Dittrich C; Durán I; Jagdev S; Millard FE; Sweeney CJ; Bajorin D; Cerbone L; Quinn DI; Stadler WM; Rosenberg JE; Lochheed M; Sen P; Squires M; Shi M; Sternberg CN
Eur J Cancer; 2014 Dec; 50(18):3145-52. PubMed ID: 25457633
[TBL] [Abstract][Full Text] [Related]
26. PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis.
Catena R; Luis-Ravelo D; Antón I; Zandueta C; Salazar-Colocho P; Larzábal L; Calvo A; Lecanda F
Cancer Res; 2011 Jan; 71(1):164-74. PubMed ID: 21097719
[TBL] [Abstract][Full Text] [Related]
27. Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134.
Liang SB; Yang XZ; Trieu Y; Li Z; Zive J; Leung-Hagesteijn C; Wei E; Zozulya S; Coss CC; Dalton JT; Fantus IG; Trudel S
Clin Cancer Res; 2011 Jul; 17(14):4693-704. PubMed ID: 21632854
[TBL] [Abstract][Full Text] [Related]
28. Insulin-like growth factor-1 rescues the mutated FGF receptor 3 (G380R) expressing ATDC5 cells from apoptosis through phosphatidylinositol 3-kinase and MAPK.
Koike M; Yamanaka Y; Inoue M; Tanaka H; Nishimura R; Seino Y
J Bone Miner Res; 2003 Nov; 18(11):2043-51. PubMed ID: 14606518
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
Guan M; Zhu L; Somlo G; Hughes A; Zhou B; Yen Y
Anticancer Res; 2009 Jan; 29(1):1-9. PubMed ID: 19331127
[TBL] [Abstract][Full Text] [Related]
30. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.
Chitta K; Paulus A; Akhtar S; Blake MK; Caulfield TR; Novak AJ; Ansell SM; Advani P; Ailawadhi S; Sher T; Linder S; Chanan-Khan A
Br J Haematol; 2015 May; 169(3):377-90. PubMed ID: 25691154
[TBL] [Abstract][Full Text] [Related]
31. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.
Li N; Lopez MA; Linares M; Kumar S; Oliva S; Martinez-Lopez J; Xu L; Xu Y; Perini T; Senapedis W; Baloglu E; Shammas MA; Hunter Z; Anderson KC; Treon SP; Munshi NC; Fulciniti M
Clin Cancer Res; 2019 Jan; 25(1):369-377. PubMed ID: 30206161
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
[TBL] [Abstract][Full Text] [Related]
33. Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.
Mazzola CR; Siddiqui KM; Billia M; Chin J
Expert Opin Investig Drugs; 2014 Nov; 23(11):1553-62. PubMed ID: 25284004
[TBL] [Abstract][Full Text] [Related]
34. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
35. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
36. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
Moreau AS; Jia X; Ngo HT; Leleu X; O'Sullivan G; Alsayed Y; Leontovich A; Podar K; Kutok J; Daley J; Lazo-Kallanian S; Hatjiharissi E; Raab MS; Xu L; Treon SP; Hideshima T; Anderson KC; Ghobrial IM
Blood; 2007 Jun; 109(11):4964-72. PubMed ID: 17284528
[TBL] [Abstract][Full Text] [Related]
37. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
Xin X; Abrams TJ; Hollenbach PW; Rendahl KG; Tang Y; Oei YA; Embry MG; Swinarski DE; Garrett EN; Pryer NK; Trudel S; Jallal B; Mendel DB; Heise CC
Clin Cancer Res; 2006 Aug; 12(16):4908-15. PubMed ID: 16914579
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
Laing N; McDermott B; Wen S; Yang D; Lawson D; Collins M; Reimer C; Hall PA; Andersén H; Snaith M; Wang X; Bedian V; Cao ZA; Blakey D
Mol Pharmacol; 2013 Jun; 83(6):1247-56. PubMed ID: 23558446
[TBL] [Abstract][Full Text] [Related]
39. Targeted therapies in Waldenström macroglobulinemia.
Burwick N; Roccaro AM; Leleu X; Ghobrial IM
Curr Opin Investig Drugs; 2008 Jun; 9(6):631-7. PubMed ID: 18516762
[TBL] [Abstract][Full Text] [Related]
40. Modulation of the activity of Bcl-2 in Waldenstrom's macroglobulinemia using antisense oligonucleotides.
Nichols GL; Stein CA
Semin Oncol; 2003 Apr; 30(2):297-9. PubMed ID: 12720156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
